Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.1
Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5-4.5 mg/dL.2
Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of US dialysis patients.3
LET'S GET STARTED
This is some text inside of a div block.
LET'S GET STARTED
WHY DO THE 3Ps MATTER?
Potency
Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.6
WHY DO THE 3Ps MATTER?
Pill Burden
Insufficient binding capacity leads to high Pill Burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.3 Half of this pill burden is from phosphate binders.7
WHY DO THE 3Ps MATTER?
Palatability
Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.8 Other binders are hard to swallow due to their large size.5 The unpalatable nature of these treatments may deter patient adherence.
Pick a tradeoff, any tradeoff!
It’s the current state of hyperphosphatemia therapies, often requiring you and your patients to choose between one inadequate treatment or another. No phosphate-lowering therapy has been able to satisfy 3 critical requirements for successful treatment: potency, pill burden, and palatability.4
Pick a tradeoff, any tradeoff!
It’s the current state of hyperphosphatemia therapies, often requiring you and your patients to choose between one inadequate treatment or another. No phosphate-lowering therapy has been able to satisfy 3 critical requirements for successful treatment: potency, pill burden, and palatability.4
WHY DO THE 3Ps MATTER?
Potency
Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.6
Pill Burden
Insufficient binding capacity leads to high Pill Burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.3 Half of this pill burden is from phosphate binders.7
Palatability
Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.8 Other binders are hard to swallow due to their large size.5 The unpalatable nature of these treatments may deter patient adherence.
WHY DO THE 3Ps MATTER?
Potency
Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.6
Pill Burden
Insufficient binding capacity leads to high Pill Burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.3 Half of this pill burden is from phosphate binders.7
Palatability
Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.8 Other binders are hard to swallow due to their large size.5 The unpalatable nature of these treatments may deter patient adherence.
Potency
Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients6.
Pill Burden
Insufficient binding capacity leads to high Pill Burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state3. Half of this pill burden is from phosphate binders7.
Palatability
Chewable binders are not preferred by most patients due to their chalkiness and metallic taste8. Other binders are hard to swallow due to their large size9. The unpalatable nature of these treatments may deter patient adherence.
One step forward. One step back.
With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorus levels due to nonadherence. Ouch!
One step forward. One step back.
With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorus levels due to nonadherence. Ouch!
One step forward. One step back.
With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorus levels due to nonadherence. Ouch!
Escape from Tradeoff Land
By enhancing potency through its patented nanoparticle technology, Unicycive aspires to finally develop a solution that satisfies all three Ps. Sign up for updates on our journey.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
References: 1. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528. doi:10.1681/ASN.2004070602 2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [published correction appears in Kidney Int Suppl (2011). 2017 Dec;7(3):e1. doi: 10.1016/j.kisu.2017.10.001]. Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001 3. US-DOPPS Practice Monitor, May 2021; http://www.dopps.org/DPM 4. Floege J. Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol. 2020 Jun;33(3):497-508. 5. Umeukeje EM, Mixon AS, Cavanaugh KL. Phosphate-control adherence in hemodialysis patients: current perspectives. Patient Prefer Adherence. 2018;12:1175-1191. 6. Huml AM, Sullivan CM, Leon JB, et al. The adequacy of phosphorus binder prescriptions among American hemodialysis patients. Ren Fail. 2012;34(10):1258-63 7. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. 8. Data on file. Unicycive Therapeutics, Inc; 2024.
